How much does Mobocertinib cost per box and analysis of medical insurance reimbursement status

Mobocertinib is an oral small molecule inhibitor that targets EGFR exon 20 insertion mutations. It is mainly used to treat non-small cell lung cancer patients with positive EGFR exon 20 insertion mutations. The drug is currently on the market in China, but it has not yet been included in the medical insurance system, so patients need to bear all costs. There are certain difficulties in purchasing moboxetinib directly in China. Patients are advised to consult the local hospital pharmacy for specific prices and purchase methods.

In terms of price, the price of domestic original drugs is relatively high, usually around 7,000 to 8,000 yuan per box. Due to the research and development costs, import fees and market supply factors of original drugs, drug prices remain at a high level. In comparison, there are also original drugs and generic drugs available in overseas markets. For example, the Hong Kong version and Japan's Takeda version of the original drug are close to or slightly higher than the domestic price, while the price of the overseas Lao version of the generic drug is significantly lower, only about 3,000 yuan, which is about half the price of the original drug.

The generic drug of mobosetinib is basically the same as the original drug in terms of drug ingredients and similar clinical effects, providing a feasible alternative for patients with limited economic conditions. The emergence of overseas generic drugs allows patients to reduce the cost of medication to a certain extent, but when purchasing, they must ensure that they are obtained through formal channels to ensure the quality and safety of the drugs.

Regarding medical insurance reimbursement, since moboxetinib has not yet been included in domestic medical insurance, patients must pay for the original drug at their own expense in China. In the future, if the drug is included in medical insurance, the price and reimbursement policy may be adjusted accordingly, thereby reducing the financial burden on patients. During use, patients should reasonably arrange their medication plan based on the doctor's guidance and their own financial situation, and at the same time pay attention to the latest developments in drug prices and medical insurance policies.

Reference link:https://www.drugs.com